<DOC>
	<DOCNO>NCT02510274</DOCNO>
	<brief_summary>The objective study ass PK , safety tolerability single oral dose ASP3325 ass PD , PK safety repeat oral dos ASP3325 administer t.i.d . meal</brief_summary>
	<brief_title>Single Multiple Dosing Study Hemodialysis Patients With Hyperphosphatemia Japan</brief_title>
	<detailed_description>[ Part 1 ] This part open-label , uncontrolled study evaluate PK safety single dose ASP3325 hemodialysis patient . After washout period therapeutic medication hyperphosphatemia , six subject receive single oral administration ASP3325 ( Tablet A ) non-dialysis day ( Day 1 ) . [ Part 2 ] This part 2-arm , open-label , uncontrolled study evaluate PD , PK safety dose ASP3325 Tablet B t.i.d . meal . Eligible subject screen enter washout period stop phosphate-binding treatment . 20 subject serum inorganic phosphorus ( Pi ) level ≥6.0 &lt; 10.0 mg/dL washout period ( washout period week 1 washout period week 2 ) randomize treatment group ASP3325 administer 2 week Day 14 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Subject receive maintenance hemodialysis 3 time week least 12 week ( 84 day ) prior schedule first day washout period . Subject receive morning dialysis start washout period end followup period . ( Part 2 ) Subject predialysis serum Pi level ≥6.0 &lt; 10.0 mg/dL confirm increase serum Pi ≥1.5 mg/dL maximum dialysis interval washout period week 1 2 . ( Part 2 ) Subject change type dose phosphate binder ( ) , nutritional supplement drug phosphorus reduce action least 4 week ( 28 day ) prior schedule first day washout period . Subject receive calcimimetics ( e.g. , cinacalcet HCl ) least 12 week ( 84 day ) prior schedule first day washout period . Subject take native active vitamin D ( include vitamin D analogue ) , calcitonin agent PTH agent must stable dose least 4 week ( 28 day ) prior schedule first day washout period . Subject history severe gastrointestinal disorder , major gastrointestinal surgery , malabsorption consider influential absorption drug nutrition gastrointestinal tract . Subject history parathyroid intervention ( e.g. , parathyroidectomy [ PTx ] , percutaneous ethanol injection therapy [ PEIT ] ) . Subject whose dry weight loss &gt; 5 % within 12 week ( 84 day ) prior schedule start day washout period . Confirmed serum intact PTH &gt; 1000 pg/mL start washout period ( applicable Part 2 ) . Subject whose last 3 measurement value separate day predialysis systolic/diastolic blood pressure schedule start day washout period washout period 180 mmHg high 120 mmHg high . Subject severe congestive heart failure ( i.e. , NYHA cardiac function classification Class III severer ) . Subject experienced myocardial infarction major surgery exclude vascular access surgery within 12 week ( 84 day ) prior inform consent signing . Subject liver function test ( ALT , AST , TBil ) range indicate screening ( Part 1 ) washout period , patient complication serious hepatic disease ( e.g. , acute active chronic hepatitis , liver cirrhosis ) . AST : &gt; 2×ULN , ALT : &gt; 2×ULN , TBil : &gt; 1.25×ULN Subject history complication malignant tumor ( consider eligible recurrence observe least 5 year ) . Subject history serious drug hypersensitivity , anaphylactic shock .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>ASP3325</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>